Kallistatin protects against diabetic nephropathy in db/db mice by suppressing AGE-RAGE-induced oxidative stress

Kidney International

Volumn 89, Issue 2, 2016, Pages 386-398

  Yiu, Wai Han ^a   Wong, Dickson W L ^a   Wu, Hao Jia ^a   Li, Rui Xi ^a   Yam, Irene ^a   Chan, Loretta Y Y ^a   Leung, Joseph C K ^a   Lan, Hui Yao ^b   Lai, Kar Neng ^a   Tang, Sydney C W ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

diabetic nephropathy; gene therapy; oxidative stress; proximal tubule; TGF beta

Indexed keywords

3 NITROTYROSINE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; CREATININE; INTERCELLULAR ADHESION MOLECULE 1; KALLISTATIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NITROGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SERINE PROTEINASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UREA; 3-NITROTYROSINE; AGER PROTEIN, MOUSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KALLIKREIN; NOX4 PROTEIN, MOUSE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TYROSINE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG MECHANISM; GENE TRANSFER; HISTOPATHOLOGY; INTRACELLULAR SIGNALING; KIDNEY FIBROSIS; MOUSE; NEPHRITIS; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; UREA NITROGEN BLOOD LEVEL; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; DIABETIC NEPHROPATHIES; FIBROSIS; GENE THERAPY; KIDNEY; KIDNEY FUNCTION TEST; MALE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ANIMALS; DIABETIC NEPHROPATHIES; FIBROSIS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; KALLIKREINS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MICE, INBRED C57BL; MICE, TRANSGENIC; NADPH OXIDASE; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SERPINS; TRANSFORMING GROWTH FACTOR BETA; TYROSINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84946140907     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2015.331     Document Type: Article

References (57)

1. G. Schernthaner, and G.H. Schernthaner Diabetic nephropathy: new approaches for improving glycemic control and reducing risk J Nephrol 26 2013 975 985
2. M.K. Arora, and U.K. Singh Oxidative stress: meeting multiple targets in pathogenesis of diabetic nephropathy Curr Drug Targets 15 2014 531 538
3. G.L. King, and M.R. Loeken Hyperglycemia-induced oxidative stress in diabetic complications Histochem Cell Biol 122 2004 333 338
4. S.Y. Goh, and M.E. Cooper Clinical review: the role of advanced glycation end products in progression and complications of diabetes J Clin Endocrinol Metab 93 2008 1143 1152
5. S.C. Tang, L.Y. Chan, J.C. Leung, and et al. Differential effects of advanced glycation end-products on renal tubular cell inflammation Nephrology (Carlton) 16 2011 417 425
6. J. Berrou, I. Tostivint, F. Verrecchia, and et al. Advanced glycation end products regulate extracellular matrix protein and protease expression by human glomerular mesangial cells Int J Mol Med 23 2009 513 520
7. N. Tanji, G.S. Markowitz, C. Fu, and et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease J Am Soc Nephrol 11 2000 1656 1666
8. T. Matsui, S. Nakashima, Y. Nishino, and et al. Dipeptidyl peptidase-4 deficiency protects against experimental diabetic nephropathy partly by blocking the advanced glycation end products-receptor axis Lab Invest 95 2015 525 533
9. A. Ojima, T. Matsui, Y. Nishino, and et al. Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor axis Horm Metab Res 47 2015 686 692
10. V. Thallas-Bonke, M.T. Coughlan, A.L. Tan, and et al. Targeting the AGE-RAGE axis improves renal function in the context of a healthy diet low in advanced glycation end-product content Nephrology (Carlton) 18 2013 47 56
11. R.E. Gilbert, and M.E. Cooper The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 56 1999 1627 1637
12. S.C. Tang, J.C. Leung, and K.N. Lai Diabetic tubulopathy: an emerging entity Contrib Nephrol 170 2011 124 134
13. S.C. Tang, J.C. Leung, L.Y. Chan, and et al. Activation of tubular epithelial cells in diabetic nephropathy and the role of the peroxisome proliferator-activated receptor-gamma agonist J Am Soc Nephrol 17 2006 1633 1643
14. S.C. Tang, L.Y. Chan, J.C. Leung, and et al. Bradykinin and high glucose promote renal tubular inflammation Nephrol Dial Transplant 25 2010 698 710
15. M. Lin, W.H. Yiu, H.J. Wu, and et al. Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy J Am Soc Nephrol 23 2012 86 102
16. R.X. Li, W.H. Yiu, H.J. Wu, and et al. BMP7 reduces inflammation and oxidative stress in diabetic tubulopathy Clin Sci (Lond) 128 2015 269 280
17. G.X. Zhou, L. Chao, and J. Chao Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence J Biol Chem 267 1992 25873 25880
18. J. Chao, A. Schmaier, L.M. Chen, and et al. Kallistatin, a novel human tissue kallikrein inhibitor: levels in body fluids, blood cells, and tissues in health and disease J Lab Clin Med 127 1996 612 620
19. A. Stadnicki, U. Mazurek, M. Gonciarz, and et al. Immunolocalization and expression of kallistatin and tissue kallikrein in human inflammatory bowel disease Dig Dis Sci 48 2003 615 623
20. L.M. Chen, Q. Song, L. Chao, and et al. Cellular localization of tissue kallikrein and kallistatin mRNAs in human kidney Kidney Int 48 1995 690 697
21. B. Shen, L. Gao, Y.T. Hsu, and et al. Kallistatin attenuates endothelial apoptosis through inhibition of oxidative stress and activation of Akt-eNOS signaling Am J Physiol Heart Circ Physiol 299 2010 H1419 H1427
22. R.Q. Miao, J. Agata, L. Chao, and et al. Kallistatin is a new inhibitor of angiogenesis and tumor growth Blood 100 2002 3245 3252
23. H. Yin, L. Gao, B. Shen, and et al. Kallistatin inhibits vascular inflammation by antagonizing tumor necrosis factor-alpha-induced nuclear factor kappaB activation Hypertension 56 2010 260 267
24. Y. Diao, J. Ma, W.D. Xiao, and et al. Inhibition of angiogenesis and HCT-116 xenograft tumor growth in mice by kallistatin World J Gastroenterol 13 2007 4615 4619
25. X. Huang, X. Wang, Y. Lv, and et al. Protection effect of kallistatin on carbon tetrachloride-induced liver fibrosis in rats via antioxidative stress PLoS One 9 2014 e88498
26. Y. Diao, X.F. Zhao, J.S. Lin, and et al. Protection of the liver against CCl4-induced injury by intramuscular electrotransfer of a kallistatin-encoding plasmid World J Gastroenterol 17 2011 111 117
27. P. Li, G. Bledsoe, Z.R. Yang, and et al. Human kallistatin administration reduces organ injury and improves survival in a mouse model of polymicrobial sepsis Immunology 142 2014 216 226
28. B. Shen, M. Hagiwara, Y.Y. Yao, and et al. Salutary effect of kallistatin in salt- induced renal injury, inflammation, and fibrosis via antioxidative stress Hypertension 51 2008 1358 1365
29. W.H. Yiu, D.W. Wong, L.Y. Chan, and et al. Tissue kallikrein mediates proinflammatory pathways and activation of protease-activated receptor-4 in proximal tubular epithelial cells PLoS One 9 2014 e88894
30. K.F. Huang, X.P. Huang, G.Q. Xiao, and et al. Kallistatin, a novel anti-angiogenesis agent, inhibits angiogenesis via inhibition of the NF-kappaB signaling pathway Biomed Pharmacother 68 2014 455 461
31. Y. Liu, G. Bledsoe, M. Hagiwara, and et al. Depletion of endogenous kallistatin exacerbates renal and cardiovascular oxidative stress, inflammation, and organ remodeling Am J Physiol Renal Physiol 303 2012 F1230 F1238
32. C.R. Wang, S.Y. Chen, C.L. Wu, and et al. Prophylactic adenovirus-mediated human kallistatin gene therapy suppresses rat arthritis by inhibiting angiogenesis and inflammation Arthritis Rheum 52 2005 1319 1324
33. J.L. Hsieh, P.C. Shen, A.L. Shiau, and et al. Adenovirus-mediated kallistatin gene transfer ameliorates disease progression in a rat model of osteoarthritis induced by anterior cruciate ligament transection Hum Gene Ther 20 2009 147 158
34. M. Sedeek, R. Nasrallah, R.M. Touyz, and et al. NADPH oxidases, reactive oxygen species, and the kidney: friend and foe J Am Soc Nephrol 24 2013 1512 1518
35. C.E. Holterman, N.C. Read, and C.R. Kennedy Nox and renal disease Clin Sci (Lond) 128 2015 465 481
36. M. Sedeek, G. Callera, A. Montezano, and et al. Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy Am J Physiol Renal Physiol 299 2010 F1348 F1358
37. M. Sedeek, A. Gutsol, A.C. Montezano, and et al. Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetes Clin Sci (Lond) 124 2013 191 202
38. J.C. Jha, S.P. Gray, D. Barit, and et al. Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy J Am Soc Nephrol 25 2014 1237 1254
39. S. Zhou, Y. Sun, Y. Zhuang, and et al. Effects of kallistatin on oxidative stress and inflammation on renal ischemia-reperfusion injury in mice Curr Vasc Pharmacol 13 2015 265 273
40. T. Nakagawa, T. Kosugi, M. Haneda, and et al. Abnormal angiogenesis in diabetic nephropathy Diabetes 58 2009 1471 1478
41. K. Ichinose, Y. Maeshima, Y. Yamamoto, and et al. 2-(8-hydroxy-6-methoxy-1- oxo-1h-2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice Diabetes 55 2006 1232 1242
42. T. Nasu, Y. Maeshima, M. Kinomura, and et al. Vasohibin-1, a negative feedback regulator of angiogenesis, ameliorates renal alterations in a mouse model of diabetic nephropathy Diabetes 58 2009 2365 2375
43. M.T. Lindenmeyer, M. Kretzler, A. Boucherot, and et al. Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy J Am Soc Nephrol 18 2007 1765 1776
44. T. Miyata, and N. Suzuki van Ypersele de Strihou C. Diabetic nephropathy: are there new and potentially promising therapies targeting oxygen biology? Kidney Int 84 2013 693 702
45. S. Yamagishi, and T. Matsui Advanced glycation end products, oxidative stress and diabetic nephropathy Oxid Med Cell Longev 3 2010 101 108
46. M.D. Oldfield, L.A. Bach, J.M. Forbes, and et al. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE) J Clin Invest 108 2001 1853 1863
47. X. Liu, B. Zhang, J.D. McBride, and et al. Antiangiogenic and antineuroinflammatory effects of kallistatin through interactions with the canonical Wnt pathway Diabetes 62 2013 4228 4238
48. J. Zhang, Z. Yang, P. Li, and et al. Kallistatin antagonizes Wnt/beta-catenin signaling and cancer cell motility via binding to low-density lipoprotein receptor-related protein 6 Mol Cell Biochem 379 2013 295 301
49. Y. Guo, L. Xiao, L. Sun, and et al. Wnt/beta-catenin signaling: a promising new target for fibrosis diseases Physiol Res 61 2012 337 346
50. A. Fornoni, A. Ijaz, T. Tejada, and et al. Role of inflammation in diabetic nephropathy Curr Diabetes Rev 4 2008 10 17
51. J. Wada, and H. Makino Inflammation and the pathogenesis of diabetic nephropathy Clin Sci (Lond) 124 2013 139 152
52. A.J. Jenkins, J.D. McBride, A.S. Januszewski, and et al. Increased serum kallistatin levels in type 1 diabetes patients with vascular complications J Angiogene Res 2 2010 19
53. J.D. McBride, A.J. Jenkins, X. Liu, and et al. Elevated circulation levels of an antiangiogenic SERPIN in patients with diabetic microvascular complications impair wound healing through suppression of Wnt signaling J Invest Dermatol 134 2014 1725 1734
54. J. Chao, J.N. Stallone, Y.M. Liang, and et al. Kallistatin is a potent new vasodilator J Clin Invest 100 1997 11 17
55. S.C. Tang, J.C. Leung, L.Y. Chan, and et al. Renoprotection by rosiglitazone in accelerated type 2 diabetic nephropathy: role of STAT1 inhibition and nephrin restoration Am J Nephrol 32 2010 145 155
56. S.C. Tang, L.Y. Chan, J.C. Leung, and et al. Additive renoprotective effects of B2-kinin receptor blocker and PPAR-gamma agonist in uninephrectomized db/db mice Lab Invest 91 2011 1351 1362
57. X. Zhong, A.C. Chung, H.Y. Chen, and et al. miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes Diabetologia 56 2013 663 674